Join us for an insightful webinar where experts from Shields' Trade Relations, Public Policy, Clinical Outcomes, and Payer Contracting teams will discuss recent biosimilar launches and upcoming market trends. Don't miss out - https://lnkd.in/dD9JAXey #TeamShields #ElevatingSpecialtyPharmacy #Biosimilar
Shields Health Solutions’ Post
More Relevant Posts
-
Corganics® is built different in every aspect from product development to commercial strategy.
Caring for your patients starts with quality, education, and transparency. Discover why healthcare professionals trust Corganics, the leading clinical cannabinoid brand. #livecorganics #cannabinoidtherapy
To view or add a comment, sign in
-
Caring for your patients starts with quality, education, and transparency. Discover why healthcare professionals trust Corganics, the leading clinical cannabinoid brand. #livecorganics #cannabinoidtherapy
To view or add a comment, sign in
-
Caring for your patients starts with quality, education, and transparency. Discover why healthcare professionals trust Corganics, the leading clinical cannabinoid brand. #livecorganics #cannabinoidtherapy
To view or add a comment, sign in
-
Sarfaraz K. Niazi, PhD, has long discussed the challenges with PBMs that plague the biosimilar industry. Join us as he addresses the NYT article where the FTC exposes the middlemen keeping you from more affordable medications and the new legislation that attempts to reform their practices and encourage biosimilar adoption. https://lnkd.in/eJaJ929c
To view or add a comment, sign in
-
FY25 HHS Budget Eliminates The Separate Interchangeability Designation For Biosimilars Eliminate the Statutory Distinction Between the Approval Standard for Biosimilar and Interchangeable Biosimilar Products and Deem that Approved #Biosimilars are #Interchangeable. The statutory distinction between biosimilars and interchangeable biosimilars has led to confusion and misunderstanding, including among patients and healthcare providers, about the safety and effectiveness of biosimilars and about whether interchangeable biosimilars are safer or more effective than other biosimilars. #FDA is seeking to amend section 351 of the Public Health Service (PHS) Act to no longer include a separate statutory standard for a determination of interchangeability and to deem all approved biosimilars to be interchangeable with their respective reference products. This proposal would make the U.S. biosimilar program more consistent with current scientific understanding as well as with the approach adopted by other major regulatory jurisdictions such as the European Union where biosimilars are interchangeable with their respective reference products upon approval.
To view or add a comment, sign in
-
Market access for biosimilars is evolving rapidly. Our team is helping our clients navigate this dynamic market successfully. #marketaccess #biosimilars #interchangeability #AmplityHealth #healthcareconsulting
Biosimilar interchangeability seems to have been acknowledged and accepted by payers as a relevant differentiator for formulary inclusion and placement. This is despite the FDA’s continued assurance that interchangeability does not indicate a superior product. In a recent article featured in Life Science Leader magazine, co-author Nikolina Janakievski, PharmD, Amplity Health’s Associate Director of Market Access, highlights the impact of interchangeability on Humira, as well as the FDA’s current efforts to minimize the significance of this designation to stakeholders in advance of dispensing medication. Read the article https://bit.ly/3HhRWWk
To view or add a comment, sign in
-
Excited to share that I’ll be presenting solutions for tackling pharmaceutical impurities at the Pharma Conclave on September 13, 2024! Join us as I delve into innovative strategies for addressing complex issues such as pharmaceutical impurities. Leveraging the cutting-edge Shimadzu LC & UFMS technologies, we’ll explore how these advancements are revolutionizing the industry. #PharmaConclave #PharmaceuticalImpurities #GenotoxicImpurities #NitrosamineImpurities
We welcome Dr. Dr. Santosh Bhardwaj on board as our distinguished speaker at the 2nd Annual Pharma Impurity Conclave 2024. He will talk about Shimadzu’s advanced technologies and how scientists can achieve greater precision in impurity analysis, ensuring compliance with stringent regulatory standards and ultimately safeguarding patient health. Register now: https://lnkd.in/gMdQsYvw #ebmpic2024 #eminencebusinessmedia #eminencegroupventures
To view or add a comment, sign in
-
ArLAR is dedicated to enhancing the quality of rheumatology care, advancing professional development, and fostering impactful research and education across the Arab countries.
Survey Alert! The ARCH – ArLAR is inviting you to a new survey! 🔴Who can participate? All rheumatologists practicing in the Arab countries 🔴What is the topic: Your opinion on the prescription of biosimilars 🔴How to participate: Follow the link: https://t.co/BRqaw8kYGE
To view or add a comment, sign in
-
My article makes the top 5 like the past weeks; the issues are real; the solutions amorphous. There is a need to crystallize our understanding of biosimilars. It will happen eventually.
To view or add a comment, sign in
-
As Humira biosimilars gain traction, there’s never been a better time to explore how they can support your clients' healthcare cost goals. We’ve seen the positive shift toward biosimilars firsthand. With lower costs and improved patient access, biosimilars can help you achieve those cost-containment goals, deliver real value to your clients, and fit your strategy. Read more on biosimilar market trends and learn about our Biosimilar Advantage Formulary. https://okt.to/IRmvG6 #Biosimilars #PharmacistsAtYourService
Biosimilars and Their Impact on Humira's Market Share
To view or add a comment, sign in
21,164 followers